Abstract-In this paper, the study of the robustness of the positive control law introduced in [1] in the presence of parameter uncertainties is made. This controller was developed to track a desired reference level for the BIS of a patient by means of the simultaneous administration of propofol and of remifentanil. Here, it is proven that in the presence of uncertainties in the BIS model, the controller still has a good performance and the BIS of the patient converges to clinically acceptable values. These results are illustrated by simulations.
I. Introduction
General anesthesia has three components: neuromuscular blockade, analgesia and hypnosis. These two latter components constitute the depth of anesthesia (DoA), which may be measured ( [2] , [3] , [4] , [5] , [6] ) by the Bispectral index (BIS). The BIS is a neurophysiologic value obtained through electroencephalogram analysis, ranged from 0 (no brain activity) to 97.7 (patient completely awake). Usually the clinical desired BIS level is defined within an interval, according to the clinical surgical procedure.
A nonlinear automatic positive control law to track a desired BIS level, by means of the administration of the analgesic remifentanil and the hipnotic propofol, was designed in [1] . This controller, already successfully implemented in clinical environment, is based on the parameter parsimonious model (PPM) (see [7] ). As the identification of the model parameters influences the performance of this control law, a method for parameter identification was developed in [8] . The problems raised by the presence of uncertainties in the parameters of the nonlinear part of the PPM was studied in [9] and a retuning strategy in order to overcome this problem was developed in [10] .
Here, it is proven that in the presence of uncertainties in the parameters of the linear part of the BIS model, the controller still has a good performance and the BIS of the patient converges to clinically acceptable values. These results are illustrated by simulations.
The structure of this paper is as follows. Section 2 is devoted to the explanation of the PPM while the control law is presented in Section 3. In Section 4 the theoretical study of the robustness of the controller in the presence of parameter uncertainties is made. Simulation results are presented in Section 5 and conclusions are drawn in Section 6.
II. Model description
The patient BIS response to the administration of propofol and of remifentanil has been recently modeled in [7] by a Wiener model with a small number of parameters, known as parameter parsimonious model (PPM). According to this model, the linear relations between the propofol and remifentanil dosages and the corresponding effect concentrations (c 
respectively, where α and η are patient dependent parameters, without any physiological meaning, and u p (s) and u r (s) are the Laplace transforms of the administered doses of propofol, u p (t), and of remifentanil, u r (t), in mg min −1 . The corresponding BIS level, z(t), usually given by the generalized Hill equation [11] , is approximated in [7] by the nonlinear equation:
where μ and γ are patient dependent parameters, without any physiological meaning, z 0 is the BIS level at zero concentration, and EC 
The states of Σ p and of Σ r are respectively denoted by x p and x r ; the third components of these vectors correspond to the effect concentrations of propofol and of remifentanil, respectively, whereas the other components have no physiological meaning. The specific form of the realizations Σ p and Σ r was chosen so as to have state space systems with a compartmental structure. As should be seen, this has the advantage of allowing the use of the positive control law defined in the next section.
This yields the following equations:
where the entries 0 should be interpreted as null submatrices of adequate dimensions.
III. Depth of anesthesia controller
In order to track a desired reference value for the BIS level, by means of simultaneous administration of propofol and of remifentanil, a nonlinear controller was presented in [1] (see also [13] ). This controller results from a combination of a linear control law with a positivity constraint for the drug doses. More concretely, the controller is defined by:
where u p is the input of propofol and u r is the input of remifentanil, with:
and
m ρ,μ = 3(0.1ρ + 100) 0.1μρ + 100 (13)
z * is the desired BIS level, and λ and ρ are positive design parameters that do not affect the tracked reference value and can be chosen according to clinical criteria. The parameter λ influences the convergence speed to the desired reference value and the parameter ρ can be interpreted as the proportion between the doses of propofol and remifentanil. Note that the matrix E is such that
For more details about this controller and its tracking properties, the reader is referred to [1] .
IV. DoA controller robustness In this section, the robustness of the control law (9) under the presence of uncertainties in the parameters of the linear part of the PPM is analyzed. The description of the controller action under parameter uncertainties is made in the next subsection and its robustness is studied in the following one.
A. Controller with uncertainties
In practice, the true values of α and η of the PPM are unknown and estimated valuesα andη are used instead. This means that estimated control dosesû p of propofol and u r of remifentanil are used. These doses are computed as
wherê
For technical reasons we define
and write the matrixÊ as:
Thenû may be written aŝ
B. Robustness analysis
In order to study the robustness of the DoA controller under parameter uncertainty, the following auxiliary output is considered:
It was proven in [1] that if in steady state M (x) =M , then the steady state BIS of the patient,z, is equal toz
This implies that, when M (x) converges to M * (as in equation (12)), the BIS of the patient converges to the reference value z * .
Since there is a relation between the output M (x) and the BIS of the patient, in a first step, the influence of the parameter uncertainties on the auxiliary output M (x) is studied. More concretely, we shall prove that, for suitable values of the design parameter λ, when the estimated control law (16) is applied to the PPM given by (5) with true parameters α and β, M (x) converges to an interval I M , which contains M * . For this purpose we define:
and Δ KA = KA − KÂ.
Taking into account that:
and that
the following inequalities, that will be useful later on, hold:
Let
We next prove that M (x) converges to I M . For this purpose, we apply the LaSalle's invariance principle (see [14] ) to the Lyapunov function V : R n −→ R defined by:
V (x) is a LaSalle-Lyapunov function of the system on R n + because it is continuous and its time derivative along the close-loop system trajectories,V (x), satisfieṡ V (x) ≤ 0, ∀x ∈ R n + , as shown next. Indeed,V (x) is given by:
withṀ (x) = Kẋ = KAx + KBû.
The study of the non positivity ofV is divided into two cases. First we consider M (x) <M min and prove that in this case M (x) > 0, implying thatV < 0. Second, we analyze the case when M (x) >M max and verify that in this case M (x) < 0 and thenV < 0, as well.
, and consequentlŷ u > 0. Thenû =û andṀ (x) becomes:
The relation between expressions (41) and (42) is due to the fact that every a ∈ R satisfies a ≥ −|a|, whereas the relation between expressions (42) and (43) results from (28) and (29).
because all the components of x are nonnegative. Ifû > 0, thenû =û andṀ (x) becomes (see equation (41)):
for kλ > |Δ ks |.
ThusV (x) is indeed nonpositive, provided that the value of the design parameter λ is taken larger than |Δ ks | k , and by the LaSalle's invariance principle, all system trajectories, x(t), converge to the largest set contained in
which is forward-invariant under the closed-loop dynamics. It follows from (36) thatV (x) = 0 either when u =ũ and
, or when u = 0, which implies that M (x) > M * , and KAx = 0. So we get
The set I 4 is not invariant. In fact, ifû would remain equal to zero, at a certain time instant, M (x) would become smaller than M * ,û(x) would become positive, andû(x) would equalû(x), so the trajectory x(t) would leave the subset. On the other hand, both I 1 , I 2 and I 3 are subsets of I M , which is invariant, indeed if M (x) ≤M min , thenṀ (x) ≥ 0 and if M (x) ≥M max , thenṀ (x) ≤ 0. Therefore, one may conclude that M (x) converges to (a subset contained in) the interval I M as previously claimed.
Since the patient BIS response to the administered drug dosesû is a decreasing function of M (x) (cf. equation (23)), the BIS level converges to the interval:
with
(66)
As expected, the desired steady state value z * is not achieved, but the patient's BIS remains in a neighborhood of this target value. Moreover, when the errors in the parameters go to 0, and hence s goes to 0 and k goes to 1 (see the remark below),M min ,M max and M (x) converge to M * . This implies that the patient BIS converges to the desired value z * , which means that the control law is robust with respect to parameter uncertainties. Moreover, as can be seen by expressions (31) and (32), increasing the parameter λ decreases the width of the interval I M and consequentely the robustness of the controller is also increased.
Remark:
Recall that:
thus, if Δ α and Δ η converge to zero k clearly converges to the value 1.
V. Simulations In this section, the performance of the control law (9) under the presence of uncertainties in the parameters on the linear part of the PPM is illustrated by means of simulations. For this purpose, a test patient was considered modeled by a PPM with realistic parameters: α = 0.068, η = 0.337, μ = 1.14, and γ = 4.12 (see Fig. 1 . BIS evolution in the presence of uncertainties,α = 0.5α, η = 0.5η. The reference value for the BIS level was set to be 50. [12] ). On the other hand, the control law was tuned with z 0 = 97.7 and the design parameters λ = 100 and ρ = 600. The desired reference value for the BIS, z * , was set to be 50. Figure 1 shows the BIS response of the patient using the controller (16) tuned for estimated parameterŝ α = 0.5α = 0.034 andη = 0.5η = 0.1685. These values correspond to an estimation error of 50%. As theoretically proved, the BIS converged to the interval
with BIS min = 49.7 and BIS max = 50.3. In spite of the error of 50% in the parameters, the interval I BIS is very narrow and the BIS nearly converged to the desired value 50.
The BIS evolution of the patient under the presence of an error of 90% in the estimation of the parameters is illustrated in Fig. 2 . In this case, the controller (16) was tuned for estimated parametersα = 1.9α = 0.1292 and η = 1.9η = 0.6403. As in the previous simulation, the BIS of the patient also converged to the interval I BIS , now with BIS min = 48.1 and BIS max = 51.8. Although the parameter estimates presents an error of 90%, the BIS of the patient also nearly converged to 50.
VI. Conclusion
In this paper, the robustness of the nonlinear control law proposed in [1] , in order to control the BIS level of patients by means of simultaneous administration of propofol and remifentanil, was studied. It was theoretically proven that even in the presence of model uncertainties, the BIS of the patient converges to an interval that contains the desired reference value for the BIS. Moreover, the presented simulations suggest that, under these circumstances, the BIS also converges to a constant value within the expected range. A study of this conjecture is the subject of ongoing research. VII. Acknowledgments
